Subject Areas on Research
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
- An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
- Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.
- Bispecific Antibodies Against HIV.
- Bispecific antibodies engage T cells for antitumor immunotherapy.
- Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia.
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
- Clinical immunotherapy for brain tumors.
- Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
- Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.
- In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
- Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
- Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
- Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
- Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Keywords of People